Table 4 Information related to the neoadjuvant treatment group before and after neoadjuvant treatment
Pre-neoadjuvant therapy | Post-neoadjuvant therapy | P-value | ||
|---|---|---|---|---|
T stage | 0 | 0 | 8 (21.53%) | 0.001 |
1 | 0 | 4 (11.76%) | ||
2 | 1 (2.94%) | 7 (20.59%) | ||
3 | 34 (97.06%) | 15 (44.12%) | ||
4 | 0 | 0 | ||
N stage | 0 | 0 | 19 (55.58%) | < 0.001 |
1 | 3 (8.82%) | 6 (17.65%) | ||
2 | 24 (70.59%) | 6 (17.65%) | ||
3 | 7 (20.59%) | 3 (8.82%) | ||
Clinical stage | 1 | 0 | 13 (38.24%) | < 0.001 |
2 | 0 | 6 (17.65%) | ||
3 | 27 (79.41%) | 12 (35.29%) | ||
4 | 7 (20.59%) | 3 (8.82%) | ||
pCR | 9 (26.47%) | |||
MPR | 4 (11.76%) | |||
CR | 9 (26.47%) | |||
PR | 21 (61.76%) | |||
SD | 4 (11.76%) | |||
PD | 0 | |||
TRG (tumor regression grade) | 0 | 9 (26.47%) | 0.019 | |
1 | 2 (5.88%) | |||
2 | 8 (21.53%) | |||
3 | 15 (44.12%) |